Case Reports:

This article has an addendum. Addendum in: Oncotarget. 2022; 13:1245-1245.

Hyperprogression to a dual immune blockade followed by subsequent response with cabozantinib in metastatic poor-risk clear cell renal cell carcinoma with NOTCH mutation

Javier Molina-Cerrillo _, Teresa Alonso-Gordoa, Alfredo Carrato and Enrique Grande

PDF  |  Full Text  |  How to cite  |  Press Release  |  Podcast

Oncotarget. 2020; 11:2137-2140. https://doi.org/10.18632/oncotarget.27598

Metrics: PDF 1109 views  |   Full Text 1873 views  |   ?  


Javier Molina-Cerrillo1, Teresa Alonso-Gordoa1, Alfredo Carrato1 and Enrique Grande2

1 Medical Oncology Department, Ramón y Cajal University Hospital, Madrid, Spain

2 MD Anderson Cancer Center, Madrid, Spain

Correspondence to:

Javier Molina-Cerrillo,email: [email protected]

Keywords: immunotherapy; renal cell carninoma; cabozantinib; NOTCH

Received: February 14, 2020     Accepted: April 27, 2020     Published: June 02, 2020


Currently, more and more patients receive first-line treatment with immunotherapy combinations and not all patients respond in metastatic renal cell carcinoma. After IO-IO progression, we don’t have a standard of treatment because it is not available prospective data on this setting. We present the case of a patient with metastatic renal cell carcinoma who suffered hyperprogression with IO-IO combination in first line. Second line with cabozantinib results in a deep response of the disease. We performed a Foundation One testing to the patient which showed a mutation in NOTCH. The molecular mechanism to explain patient’s response, it’s the probably crosstalk between MET and NOTCH pathway. Nowadays, there is not clear the subsequent treatment in those patients who progress to IO-IO first line. More efforts in biomarkers development should be made to better selection of patients treatment along the disease.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27598